ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$3.25
0.17 (5.36%)
▲
5d:
-2.26%
30d:
-12.53%
90d:
-24.71%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Jun 18, 2026
Smart Money Accumulation
ACB is down 6.9% this week, but smart money is accumulating calls. Top strike: $4 2026-05-15 with 250 OI. Call ratio: 100% View Scanner →
Strength: 8.5/10
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACB shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: ACB shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $3.25, which is considered oversold relative to its 30-day fair value range of $3.30 to $3.71. From a valuation perspective, the stock is trading at a discount (Forward PE: -19.6) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a strong downtrend. Immediate support is located at $3.07, while resistance sits at $3.50. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ACB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.28 (+104.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACB is in a strong downtrend. Immediate support is located at $3.07, while resistance sits at $3.50. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ACB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.28 (+104.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.30 -
$3.71
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 104.0% below Wall St target ($6.28)
Fair Price Analysis
30-Day Fair Range
$3.30 -
$3.71
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.31
(9.7%)
Support & Resistance Levels
Support Level
$3.07
Resistance Level
$3.50
Current Trend
Strong Downtrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.56
Wall Street Target
$6.28
(+104.0%)
Revenue Growth (YoY)
6.8%
Earnings Growth (YoY)
-94.7%
Profit Margin
-22.5%
PE vs Historical
-19.6 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: March 31, 2026 11:24 AM ET
Data refreshes hourly during market hours. Next update: 12:24 PM
Data refreshes hourly during market hours. Next update: 12:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
